Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2012; 18(1): 55-63
Published online Jan 7, 2012. doi: 10.3748/wjg.v18.i1.55
Published online Jan 7, 2012. doi: 10.3748/wjg.v18.i1.55
Table 2 Hepatitis C virus-RNA, alanine aminotransferase, and aspartate aminotransferase at different times of treatment and follow up
| 0 (before treatment) | 24 wk | 48 wk | 24 wk post treatment | |
| No. of patients with 2 log drop in HCV-RNA | 0 | 1 (0.05%) | 2 (0.1%) | NA |
| No. of patients with undetected HCV-RNA | 0 | 9 (47.4%) | 9 (47.4%) | 8 (42.1%) |
| Normal ALT | 10 | 14 (73.6%) | Out of all patients 15/19 (78.9%) | Out of all patients15/19 (78.9%) |
| Out of responders 9/9 (100%) | Out of responders 8/8 (100%) | |||
| Normal AST | 10 | 13 (68.4%) | Out of all patients13/19 (68.4%) | Out of all patients13/19 (68.4%) |
| Out of responders 9/9 (100%) | Out of responders 9/9 (100%) |
- Citation: Aljumah AA, Saeed MA, Al Flaiw AI, Al Traif IH, Al Alwan AM, Al Qurashi SH, Al Ghamdi GA, Al Hejaili FF, Al Balwi MA, Al Sayyari AA. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012; 18(1): 55-63
- URL: https://www.wjgnet.com/1007-9327/full/v18/i1/55.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i1.55